The primary hypothesis of this study is to determine whether the cumulative number of newly active lesions developing over a treatment period of 24 weeks, as seen on MRI scanning performed every 4 weeks, is 50% lower in any of the three Ro 45-2081 treatment groups as compared to placebo. This study aims to determine whether or not Ro 45-2081 has the potential to halt or prevent disease progression in patients with multiple sclerosis by assessing the rate of newly active lesions seen on MRI.
Showing the most recent 10 out of 244 publications